Artikel
Everolimus reduces the metastatic potential of human uveal melanoma cells
Suche in Medline nach
Autoren
Veröffentlicht: | 20. August 2013 |
---|
Gliederung
Text
Aim: Evaluation of the effect of Everolimus on the viability, proliferation, and migration of the uveal melanoma cell line 92.1 as well as the expression of several metastatic proteins.
Methods: The 92.1 uveal melanoma cells were cultured in RPMI1640 supplemented with 10% serum and treated with Everolimus alone or combined with Rho-Kinase inhibitor H1152. Viability and proliferation were assessed by immunostaining (Ki-67, Vimentin, beta-Catenin) und des MTT-Assays. Migration was analyzed by the scratch assay on the confluent monolayers of cells grown in 6-well plates.
Results: The MTT-tests revealed a dosage-dependent decrease of proliferation of 92.1 cells after the treatment with Everolimus especially with a concentration of 100 nM. The expression of Ki-67, Vimentin and beta-Catenin as well as the cell migration into the wound area were reduced after the treatment with Everolimus.
Conclusions: Everolimus (0.1–1 μM) induces a reduction of cell survival, proliferation and migration of human uveal melanoma cells.